Clinical trial
A Phase 3, 26-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-OLE-01-VA in Participants With Mild to Moderate Alzheimer's Disease Dementia
NCT05809908 is registered in ClinicalTrials.gov with Cerecin as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, 26-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-OLE-01-VA in Participants With Mild to Moderate Alzheimer's Disease Dementia
- Lead sponsor
- Cerecin
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- July 31, 2029
- Enrollment
- 535 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.